AB2188 Explained: Understanding the Impact on Workplace Drug Testing

In recent years, the landscape of cannabis legislation has undergone significant changes, posing new challenges and considerations for employers across various industries. One such pivotal development is California Assembly Bill 2188, which is scheduled to take effect on January 1, 2024. This legislation marks a crucial shift in how employers must approach workplace drug testing, particularly concerning cannabis use. The bill’s introduction reflects evolving attitudes towards cannabis and its impact on workplace safety and employee rights.

Understanding AB2188: A Closer Look at the New Legal Framework

AB2188, approved on September 18, 2022, introduces significant changes in California employment law, specifically targeting cannabis use by employees outside the workplace. A core component of the bill is its prohibition against discrimination based on tests for non-psychoactive cannabis metabolites. It highlights a critical distinction: while THC, the psychoactive compound in cannabis, indicates impairment, its metabolites do not. These metabolites, remnants of THC processing in the body, can linger for days or weeks without implying current impairment. AB2188’s framework challenges employers to reassess their drug testing methods, shifting focus from past usage indicators to current impairment detection.

Though AB2188’s regulations are currently confined to California, they may pave the way for similar legislative trends across other states. This anticipation necessitates a forward-looking approach from businesses nationwide, urging them to reevaluate and adapt their drug testing and employment practices in line with these emerging standards.

Decoding THC Testing and Impairment: A Complex Challenge

Understanding the nuances of THC’s effects and its detection is vital in navigating the implications of AB2188. THC’s fat solubility and the body’s processing methods create a complex relationship between THC levels in the blood and actual impairment. This complexity is highlighted in the Indigent Defense Services’ “Marijuana Impairment FAQ”, which stresses that blood concentrations of THC and its metabolites are insufficient to prove impairment. Unlike alcohol, where blood concentration is a reliable impairment indicator, THC levels vary significantly based on factors like consumption methods and individual metabolism. Consequently, a positive THC test does not necessarily indicate current impairment, nor does a negative test rule it out. This inconsistency presents a significant challenge for employers in objectively assessing impairment and underscores the need for comprehensive evaluation beyond mere THC level detection.

The Ripple Effect on Employers and Occupational Health Services

The enactment of AB2188 necessitates a strategic pivot for employers, especially in industries where safety is paramount. Employers must now find reliable methods to detect acute cannabis intoxication, aligning with the law’s stipulations. This transition involves adopting new testing techniques and reevaluating workplace policies and procedures.

Guidance for Employers on Policy Update

With AB2188 reshaping the legal landscape, employers are encouraged to review and update their drug testing policies. This update should focus on adopting testing methods that accurately reflect current impairment, as opposed to past cannabis use. A crucial aspect of this process involves comprehensive documentation of all potential signs of impairment, including behavioral observations and statements from employees or co-workers. Employers should also be aware of the legal nuances, particularly in sectors exempt from certain provisions of AB2188. Consulting with legal advisors is essential to ensure state and federal regulations compliance.

Future Developments and Support from Work Health Solutions

As the science of cannabis impairment detection continues to evolve, Work Health Solutions remains committed to staying abreast of the latest developments. This includes monitoring advancements in testing technologies that could offer more precise indicators of recent cannabis consumption. Work Health Solutions provides essential support to employers navigating these changes through our Fractional Medical Director program and other services, ensuring that our approaches to workplace safety and health remain legally compliant and scientifically sound.

For a more detailed exploration of WHS’s specific initiatives and strategies in response to AB2188, employers and stakeholders are encouraged to consult with WHS directly. 

Conclusion: Staying Ahead in a Changing Environment

In conclusion, AB2188 represents a significant shift in the approach to cannabis use in the workplace, challenging employers to adapt their policies and practices. Employers can effectively navigate this changing landscape by staying informed, consulting with experts, and embracing new testing methodologies. For further guidance and support, Work Health Solutions stands ready to assist in aligning workplace practices with the latest legal and medical standards.

Work Health Solutions

Work Health Solutions

About Us

Work Health Solutions is dedicated to preserving a safe work environment and improving existing programs and care for local, regional and national organizations.

Share This Post


Recent Posts

Speak with an Occupational Health Specialist

If you have questions about Work Health Solution's occupational health services or if you need to purchase bulk medical supplies, such as COVID-19 testing kits, please contact us.

Get in Touch

Dr. Michael Tenison

A series of notable accomplishments distinguish Dr. Michael Tenison’s career in medical operations and healthcare management:

  • Successfully led medical operations at a national healthcare provider, focusing on optimizing healthcare delivery and patient outcomes.
  • Oversaw the regional medical practices in key markets like Oregon and Northern California, ensuring consistent, quality medical care and service delivery.
  • Demonstrated exceptional leadership in building and mentoring a large medical provider team, enhancing team performance and patient care standards.
  • Implemented strategic company policies and protocols, significantly improving center efficiency, clinical quality, and patient experiences.
  • Played a pivotal role in financial planning and identifying growth opportunities for healthcare services, contributing to the organization’s overall success.
  • Served as a primary point of contact for regional employer clients and insurance companies, fostering strong relationships and effective communication.
  • Maintained high medical care and case management standards through diligent supervision, chart audits, and performance metric analysis.

Dr. Matt Feeley

Dr. Matt Feeley is a renowned figure in military aviation medicine, with a robust background in occupational and environmental medicine from the Johns Hopkins Bloomberg School of Public Health. 

  • Former Naval Flight Surgeon, exemplifying his expertise in aerospace medicine and commitment to military health.
  • Served with distinction at NSA Bahrain and HSM-37, earning the COMPACFLT Flight Surgeon of the Year award for exceptional medical service.
  • Supported U.S. Marines VMFA-323 aboard the USS Nimitz, MACG-38, and VMU-3, demonstrating versatility and leadership in diverse medical environments.
  • Broad interests and significant contributions in global health, corporate medicine, and aerospace medicine, highlighting his multidisciplinary approach.
  • Proven track record as a dynamic leader, well-equipped to face the challenges in a fractional medical directorship role with innovative solutions.

Dr. Glen Cheng

A physician-attorney with a dedication to healthcare innovation, informatics, and digital health.

  • Currently spearheads employee health protection and promotion within the VA Pittsburgh Health Care System.
  • Trained in residency at Harvard, achieving board certification as a physician; also a licensed patent attorney with experience as FDA regulatory counsel.
  • Co-founded Acceleromics, a consulting firm providing clinical and regulatory guidance to digital health startups.

Erin Davis

 Chief Clinical Officer at Work Health Solutions, certified in Adult-Gerontology (AGNP-C) and Athletic Training (ATC).

  • Oversees clinical operations and ensures high clinical standards across the company’s national field staff.
  • Former Manager of Clinic Operations and Occupational Health Nurse Practitioner at Stanford University Occupational Health Center (SUOHC).
  • Specialized in treating occupational injuries and illnesses, and provided medical surveillance and travel medicine consults at Stanford and SLAC National Accelerator Lab.
  • Dedicated to sports and occupational injury treatment and prevention.
  • Assistant Clinical Faculty at UCSF, mentoring students in clinical rotations within the Adult Gerontology and Occupational and Environmental Health Program.
  • Holds leadership roles as Treasurer and President Elect of the California El Camino Real Association of Occupational Health Nurses (CECRAOHN), affiliated with the American Association of Occupational Health Nurses (AAOHN).

Dr. Robert Goldsmith

Expert in benefits design and onsite innovation with specialization in the pharmaceutical industry.

  • Previous role as Executive Director for Employee Health at Novartis Services, Inc., leading health services and clinical support.
  • Instrumental in creating an integrated healthcare system at Novartis.
  • Former private practice in internal medicine in Stamford, Connecticut, and Medical Director consultant for GTE Corporation.
  • Transitioned to GE as a Global Medical Director in 2000.
  • Holds a medical degree from Albert Einstein College, an MPH from the University of Connecticut, and completed training at Greenwich Hospital and Yale-New Haven Medical Center.
  • Assistant professor in the Department of Medicine at the Vagelos School of Medicine, Columbia University.
  • Serves as a team physician for high school athletes in Stamford.
  • Published works on occupational health risks, primary prevention, and exercise-induced asthma.